阿斯利康AstraZeneca plc （AZN） 2021年可持续发展报告「LSE」.pdf

1、SustainabilityReport2021Unlocking the potential of the complement system The dysregulation of the complement system,an essential part of the immune system,is a key driver of many devastating diseases.Targeting and inhibiting the complement system before it can trigger tissue damage ordestruction can

2、 help restore balance.We are committed tocontinue unlocking the potential of the complement system,to discover new life-changing therapies for even more patients.AssuranceWe obtained external review of our sustainability performance to validate that we use the same rigour and accuracy as we do with

3、regulated reporting.Bureau Veritas has provided independent external assurance for progress on all sustainability targets and all sustainability key performance indicators shown in the Sustainability Data Summary.Details are described in the sustainability letter of assurance.Assurance was also prov

4、ided for select sustainability information in the 2021 Annual Report.Assurance is in accordance with the International Standard on Assurance Engagements 3000(ISAE 3000),and ISAE 3410 Assurance Engagements on Greenhouse Gas Statements.This report:This is our seventh annual sustainability report and i

5、t describes our approach and progress from 1 January 2021 to 31 December 2021,unless otherwise stated.The content of this report is based on those sustainability focus areas deemed material through comprehensive stakeholder engagement and analysis.Allour business operations worldwide are in scope re

6、gardless of their function,unlessotherwise stated.Online resources:AstraZeneca Sustainability Data Summary:provides performance measures and targets with at least three years of data,where available,and a United Nations Sustainable Development Goals index.AstraZeneca Sustainability webpages:cover ad